Alexandria Capital’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Alexandria Capital’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-50	Closed	–	–	589
2017 Q3	$0	Hold	50	–	–	﹤0.01%	647
2017 Q2	$1K	Hold	50	–	–	﹤0.01%	607
2017 Q1	$1K	Hold	50	–	–	﹤0.01%	599
2016 Q4	$1K	Hold	50	–	–	﹤0.01%	580
2016 Q3	$1K	Hold	50	–	–	﹤0.01%	591
2016 Q2	$1K	Hold	50	–	–	﹤0.01%	587
2016 Q1	$1K	Hold	50	–	–	﹤0.01%	589
2015 Q4	$1K	Hold	50	–	–	﹤0.01%	639
2015 Q3	$2K	Hold	50	–	–	﹤0.01%	555
2015 Q2	$2K	Hold	50	–	–	﹤0.01%	576
2015 Q1	$2K	Hold	50	–	–	﹤0.01%	587
2014 Q4	$2K	Hold	50	–	–	﹤0.01%	550
2014 Q3	$1K	Hold	50	–	–	﹤0.01%	554
2014 Q2	$1K	Hold	50	–	–	﹤0.01%	574
2014 Q1	$2K	Hold	50	–	–	﹤0.01%	561
2013 Q4	$2K	Hold	50	–	–	﹤0.01%	569
2013 Q3	$3K	Hold	50	–	–	﹤0.01%	548
2013 Q2	$3K	Buy	+50	New	+$2.5K	﹤0.01%	601

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Alexandria Capital's NAVB Position: Q4 2017 in Review

Alexandria Capital sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2017, closing a stake of 50 shares.

Alexandria Capital first reported a position in NAVB in Q2 2013 and held it in 18 quarters. The position peaked at $3K in Q3 2013. 54 funds tracked by Wall St. Rank hold NAVB as of Q4 2017.

Alexandria Capital reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2017 after selling out during the quarter.
Alexandria Capital sold 50 Navidea Biopharmaceuticals Inc. shares in Q4 2017.
Alexandria Capital first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 18 quarters.
Alexandria Capital's Navidea Biopharmaceuticals Inc. position peaked at $3K in Q3 2013.
54 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2017.

Based on Alexandria Capital's 13F filing for Q4 2017, filed 9 Feb 2018.